BB 10010

Drug Profile

BB 10010

Alternative Names: Macrophage inflammatory protein-1-alpha analogue; MIP-1alpha variant; Nagrestip

Latest Information Update: 07 May 2003

Price : $50

At a glance

  • Originator British Biotech
  • Class Radioprotectives
  • Mechanism of Action Immunosuppressants; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemoprotection; HIV infections; Myeloid leukaemia; Radioprotection

Most Recent Events

  • 07 May 2003 A study has been added to the Cancer therapeutic trials section
  • 29 Feb 2000 A preclinical study has been added to the pharmacodynamics section
  • 29 Feb 2000 Preclinical development for Chemotherapy induced damage (Prevention)/Chemoprotection in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top